Scientific Study: Potential Use of Cellular Stromal Vascular Fraction in Post-COVID-19 Pulmonary Injury and Adult Respiratory Distress Syndrome
SDARTs faculty member, Robert W. Alexander, MD, DDS, is the Principle Investigator on a first-in-human clinical trial using AD cSVF to treat post-COVID 19 survivors suffering residual lung damage.
Many moderate to severe post-COVID 19 survivors experience compromised lung function. As a proposed solution, adipose-derived cellular stromal vascular fraction (AD cSVF) may be effective in reversing residual damage to the lungs and gas exchange functions.
This study was published in the Journal of Current Medical Research and Opinion.